Dec 30, 2025 • Stock Traders Daily
SOMEWHAT-BULLISH
The Technical Signals Behind (ASND) That Institutions Follow
This article provides a technical analysis of Ascendis Pharma A/s (NASDAQ: ASND), highlighting institutional trading strategies and AI-generated signals. It identifies a mid-channel oscillation pattern and offers entry/target/stop-loss points for long, breakout, and short positions across near-term, mid-term, and long-term horizons, focusing on risk management.
Dec 25, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Buy" from Analysts
Ascendis Pharma A/S (NASDAQ:ASND) has received an average "Buy" recommendation from seventeen analysts, with a consensus 12-month price target of $256.73. The company recently reported a quarterly EPS miss but revenue slightly beat estimates, and several institutional investors have increased their stakes. ASND shares are currently trading around $212.71 with a market capitalization of $13.17 billion.
Dec 25, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of "Buy" by Analysts
Ascendis Pharma A/S (NASDAQ:ASND) has received an average "Buy" recommendation from seventeen research firms, with a mean one-year price target of $256.73. Despite missing Q3 EPS estimates, the company's revenue exceeded expectations, and significant institutional investors have increased their stakes. The stock opened at $212.71, with a market cap of $13.17 billion, reflecting strong institutional confidence alongside analyst optimism.
Dec 25, 2025 • MarketBeat
NEUTRAL
ARS Investment Partners LLC Decreases Stock Position in Ascendis Pharma A/S $ASND
ARS Investment Partners LLC reduced its stake in Ascendis Pharma A/S by 16.3% in Q3, selling 34,263 shares. Despite this, Ascendis Pharma remains the 15th largest position in ARS Investment Partners' portfolio, and several other major institutions have recently increased their holdings or initiated new positions. Ascendis Pharma A/S (NASDAQ:ASND) has a consensus Buy rating from analysts with an average target price of $256.73, although the company recently missed EPS expectations.
Dec 23, 2025 • MarketBeat
NEUTRAL
Squarepoint Ops LLC Buys Shares of 5,197 Ascendis Pharma A/S $ASND
Squarepoint Ops LLC recently initiated a new position in Ascendis Pharma A/S (NASDAQ:ASND), purchasing 5,197 shares valued at $897,000 in Q2. This move is part of broader institutional interest, with other firms like Goldman Sachs and Marshall Wace also increasing their stakes. Despite analysts maintaining an average "Buy" rating with a target of $256.73, Ascendis Pharma missed its recent EPS estimates, though its stock remains up approximately 4.7%.
Dec 19, 2025 • 富途牛牛
BULLISH
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $305
Evercore analyst Gavin Clark-Gartner has reiterated a Buy rating for Ascendis Pharma A/S (ASND.US), maintaining a target price of $305. According to TipRanks data, the analyst has a 66.7% success rate and a 25.6% average return over the past year. This report emphasizes the analyst's continued positive outlook on the biopharmaceutical company.